SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Follow-up) — Gilda Radner — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientGilda Radner
Date of birth1946-06-28
IdentifiersMRN HR-ML026-SYN-TD; SSN (made up) 000-26-8821
Document date1986-07-14
AuthorDelia Marchand, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Review at the midpoint of chemotherapy, on the day of cycle 4. [S]

History of Present Illness

Ms. Radner returns on the day of her fourth cycle of carboplatin and paclitaxel. Cycles 2 and 3 were given on schedule. The cold she had a week after cycle 2 cleared in five days without a fever. Nausea lasts a day or two after each cycle and is controlled with ondansetron, which she uses two or three times per cycle. For about two weeks she has had tingling in her toes and fingertips that does not stop her buttoning clothes, walking, or writing. Her hair has fallen out and she wears a scarf. Hot flashes continue. She goes to her support group every other week. She has had no thoughts of self-harm. [S]

ElementDetail
TreatmentCycle 4 of 6 today; cycles 2 and 3 on schedule
NauseaOne or two days after each cycle; ondansetron two or three times
NeuropathyTingling in the toes and fingertips for two weeks; no effect on function
InfectionCold after cycle 2 resolved without fever
MoodPHQ-9 4; support group every other week

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired for a few days after each cycle; no fever
GastrointestinalPositiveNausea for one or two days after each cycle; no vomiting; bowels regular
NeurologicalPositiveTingling in the toes and fingertips; no weakness or falls
IntegumentaryPositiveHair loss
EndocrinePositiveHot flashes
RespiratoryNegativeCough gone; no breathlessness
PsychiatricNegativeMood steady; no thoughts of self-harm

7 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Enoxaparin 40 mg/0.4 mL prefilled syringe, 40 mg under the skin once daily for 28 days after surgery40 mg under the skin once daily for 28 daysSubcutaneous route1986-04-21 to 1986-05-18completedS
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain after surgery, no more than 3 g a dayTwo tablets every 6 hours as neededOral route1986-04-21 to 1986-05-05completedS
Carboplatin 10 mg/mL injection, 610 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cyclesDay 1 every 21 days for six cyclesIntravenous route1986-05-12 to 1986-08-25completedS
Paclitaxel 6 mg/mL injection, 275 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidineDay 1 every 21 days for six cyclesIntravenous route1986-05-12 to 1986-08-25completedS
Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nauseaOne tablet every 8 hours as needed for nauseaOral route1986-05-12activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1986-07-14Body height160cmS
1986-07-14Body weight55.9kgS
1986-07-14Body mass index (BMI) [Ratio]21.8kg/m2S
1986-07-14Systolic blood pressure110mm[Hg]S
1986-07-14Diastolic blood pressure70mm[Hg]S
1986-07-14Heart rate80/minS
1986-07-14Respiratory rate14/minS
1986-07-14Body temperature36.6CelS
1986-07-14Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1986-07-14Hemoglobin [Mass/volume] in Blood10.3g/dL11.6-15 g/dLLowS
1986-07-14Leukocytes [#/volume] in Blood by Automated count4.110*3/uL4-11 10*3/uLNormalS
1986-07-14Neutrophils [#/volume] in Blood by Automated count1.910*3/uL1.5-7.7 10*3/uLNormalS
1986-07-14Platelets [#/volume] in Blood by Automated count18810*3/uL150-400 10*3/uLNormalS
1986-07-14Creatinine [Mass/volume] in Serum or Plasma0.7mg/dL0.59-1.04 mg/dLNormalS
1986-07-14Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1981)/1.73 sq M113mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1986-07-14Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L7-35 U/LNormalS
1986-07-14Bilirubin.total [Mass/volume] in Serum or Plasma0.4mg/dL0.1-1.2 mg/dLNormalS
1986-07-14Magnesium [Mass/volume] in Serum or Plasma1.7mg/dL1.7-2.2 mg/dLNormalS
1986-07-14Cancer Ag 125 [Units/volume] in Serum or Plasma21U/mL<=35 U/mLNormalS
1986-07-14Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S

Physical Exam

Vital signs recorded on 1986-07-14; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 55.9 kg; blood pressure 110/70, pulse 80
AbdomenSoft, non-tender; no fluid or mass
NeurologicalPinprick slightly reduced over the toes; vibration sense and ankle reflexes present; strength normal; steady gait
SkinAlopecia; no rash
PsychiatricBright, engaged; organized

Problems

ProblemClinical statusVerificationCodeProvenance
Persistent bloating with tightness of her clothes, feeling full after a few bites, a dull lower abdominal and pelvic ache, and passing urine more often, on most days for about four weeks, in a woman of 39: the ovarian cancer symptom index is positive. Examination: a distended abdomen with shifting dullness and a firm, fixed, irregular mass in the right adnexa. Suspected ovarian cancer; transvaginal ultrasound, CT, CA-125 and gynecologic oncology review booked within the weekresolvedconfirmed R19.00S — Synthetic presenting problem linked to her documented abdominal symptoms; superseded by the diagnosis at the gynecologic oncology consultation.
High-grade serous carcinoma of both ovaries (Mullerian origin), diagnosed by image-guided omental core biopsy (PAX8 and WT1 positive, p53 aberrant), with bilateral adnexal masses, ascites, omental and diaphragmatic disease on CT: clinical FIGO stage IIIC; synthetic modern detail linked to her documented ovarian canceractiveconfirmed C56.3S — Synthetic histology and stage; the documented diagnosis was stage IV ovarian cancer (D).
Peritoneal and omental metastases of the ovarian cancer, with ascitesactiveconfirmed C78.6S — Synthetic extent of disease on CT and biopsy.
Family history of ovarian cancer in three relatives (her grandmother, an aunt, and a cousin) in a woman of Ashkenazi Jewish ancestry; no genetic testing in the family is knownactiveconfirmed Z80.41S — Synthetic coding of her documented family history; the basis for genetic counseling.
Acute viral upper respiratory infection on day 8 of the second chemotherapy cycle: two days of sore throat, runny nose and a dry cough, without fever; rapid influenza and COVID-19 tests negative; resolvedresolvedconfirmed J06.9S — Synthetic acute infection; not a historical claim.
Symptomatic surgical menopause after bilateral salpingo-oophorectomy at 39: hot flashes and night sweatsactiveconfirmed E89.41S — Synthetic consequence of the synthetic operation.
Chemotherapy-induced peripheral neuropathy from paclitaxel: tingling in the toes and fingertips, grade 1 (sensory only, no effect on daily activities)activeconfirmed G62.0S — Synthetic common effect of paclitaxel.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBlood count with neutrophils and plateletsBefore each chemotherapy cycleCompleted todayHemoglobin 10.3 g/dL, white cells 4.1, neutrophils 1.9, platelets 188; cycle 4 can be given. Cycles 2 and 3 were given on schedule in the infusion center
LaboratoryCreatinine and estimated kidney function (carboplatin dose)Before each cycleCompleted todayCreatinine 0.70 mg/dL, eGFR 113; carboplatin dose unchanged
LaboratoryLiver tests (paclitaxel)Before each cycleCompleted todayALT 24 U/L, bilirubin 0.4 mg/dL
LaboratoryMagnesiumBefore each cycleCompleted today1.7 mg/dL, at the lower limit; dietary advice and a check before each remaining cycle
LaboratoryCA-125At diagnosis; before each cycle when raised at diagnosis; at the end of treatment; then at each surveillance visitDeferred21 U/mL today, now normal. A deviation: CA-125 was not drawn before cycles 2 and 3, which were given in the infusion center with blood counts only. No harm resulted: today's value shows a response, and imaging is planned at the end of treatment. Corrective action: CA-125 at the end of treatment and at every surveillance visit; no earlier values are recorded
ImagingResponse imagingAt the end of primary treatment, or sooner for symptoms or a rising CA-125Not indicatedNot needed at the midpoint: CA-125 normal and no symptoms; CT after cycle 6
ExaminationPeripheral neuropathy: symptoms and examinationAt baseline and before each taxane cycleCompleted todayGrade 1 sensory neuropathy; full dose continues
Medication safetyNausea and vomiting controlEach cycleCompleted todayControlled: nausea one or two days per cycle, no vomiting
Medication safetyPaclitaxel infusion reaction preventionEach paclitaxel doseCompleted todayNo reaction in three cycles; same premedication
SurveyDistress and depression screen (PHQ-9)At diagnosis, at each treatment phase, and when symptoms changeCompleted todayPHQ-9 4
Self-managementMenopausal symptoms after oophorectomyEach visit after surgeryCompleted todayHot flashes continue; managed without medicine
Self-managementInfection precautions and fever planEach cycleCompleted todayChecks her temperature after each cycle; knows to call at once for 38.0 °C or more
Self-managementPsychosocial support and informationAt diagnosis and throughoutCompleted todaySupport group every other week

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 4.2026 (2026); Salani R, et al. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 2017;146(1):3-10 (2017); Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020;38(24):2782-2797 (2020); Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (2020); Depression and Suicide Risk in Adults: Screening (2023); NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections (2026)

Follow-up: Cycles 5 and 6 every 21 days. CT about two weeks after cycle 6, then a review with the result and the maintenance decision. Next scheduled visit 1986-09-15: end of chemotherapy: CT and CA-125 response, and the start of olaparib maintenance. [S]